SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : VD's Model Portfolio & Discussion Thread
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Vector1 who wrote (5549)9/1/1998 4:46:00 PM
From: Mel Kaplan  Read Replies (1) of 9719
 
V!, I too am struck that the FDA was concerned by quality control of a complex influenza virus vaccine, composed of a mixture of heat-killed and attenuated live viral strains and produced in the UK ,supplied in
bulk to AVIR in CA for assembly and packaging.
Avir has supported the efficacy of the vaccine in terms of antibody response and clinical infection and protection from ear infection in children. In the original report, it was noted that a small number of patients developed fever after the nasal instillation, which was transient but unexplained, and dismissed. The FDA did not apparently cite this. It did not accept for filing the British papers on
the quality of the bulk product.
Rman may be right in tha whole matter can be reconciled by responses of AVIR, but the FDA is doing its job.
Mel
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News